Table 5.

Mean total duration and total errors (±SD) on GMLT tasks at baseline, and after 4, 8, and 12 weeks of Ax treatment

Group/Task	Baseline	4 weeks		8 weeks		12 weeks
	Mean ± SD	Mean ± SD	p (vs baseline)	Mean ± SD	p (vs baseline)	Mean ± SD	p (vs baseline)
Placebo group (n = 31)
Total duration (s)	158.8 ± 36.0	148.7 ± 35.6	0.193	143.0 ± 34.9	0.017*	134.4 ± 33.2	<0.001**
Total errors	74.3 ± 22.9	67.8 ± 23.3	0.925	65.1 ± 23.0	0.258	60.7 ± 25.6	0.003**
Ax low-dosage group (n = 29)
Total duration (s)	157.8 ± 25.9	147.3 ± 21.5	0.322	137.2 ± 23.8	0.002**	127.8 ± 16.2	<0.001**
Total errors	79.9 ± 31.0	63.3 ± 24.5	0.005**	61.3 ± 21.6	0.001**	57.3 ± 20.7	<0.001**
Ax high-dosage group (n = 29)
Total duration (s)	162.0 ± 44.8	153.2 ± 43.0	0.517	139.5 ± 34.3	<0.001**	135.4 ± 33.2	<0.001**
Total errors	83.0 ± 36.9	68.9 ± 33.9	0.024*	60.8 ± 24.5	<0.001**	60.6 ± 25.1	<0.001**

Dropouts were excluded from the data analysys. *p<0.05, **p<0.01 (vs baseline). Data were analyzed by one-way repeated measure ANOVA, adjusted for age and sex. Multiple comparisons of 4, 8, and 12 weeks with baseline were performed using Bonferroni correction.